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ABSTRACT
Objectives: To explore the cost-effectiveness of ﬂuticasone
propionate (FP) for the treatment of chronic obstructive pul-
monary disease (COPD), we estimated costs and quality-
adjusted life-years (QALYs) over 3 years, based on an
economic appraisal of a previously reported clinical trial
(Inhaled Steroids in Obstructive Lung Disease in Europe
[ISOLDE]).
Methods: Seven hundred forty-two patients enrolled in the
ISOLDE trial who received either FP or placebo had data
available on health-care costs and quality of life over the
period of the study. The SF-36-based utility scores for quality
of life were used to calculate QALYs. A combined imputation
and bootstrapping procedure was employed to handle miss-
ing data and to estimate statistical uncertainty in the esti-
mated cumulative costs and QALYs over the study period.
The imputation approach was based on propensity scoring
and nesting this approach within the bootstrap ensured that
multiple imputations were performed such that statistical
estimates included imputation uncertainty.
Results: Complete data were available on mortality within
the follow-up period of the study and a nonsigniﬁcant trend
toward improved survival of 0.06 (95% conﬁdence interval
[CI] –0.01 to 0.15) life-years was observed. In an analysis
based on a propensity scoring approach to missing data we
estimated the incremental costs of FP versus placebo to be
£1021 (95% CI £619–1338) with an additional effect of
0.11 QALYs (CI 0.04–0.20). Cost-effectiveness estimates
for the within-trial period of £17,700 per life-year gained
(£6900 to ∞) and £9500 per QALY gained (CI £4300–
26,500) were generated that include uncertainty due to the
imputation process. An alternative imputation approach did
not materially affect these estimates.
Conclusions: Previous analyses of the ISOLDE study
showed signiﬁcant improvement on disease-speciﬁc health
status measures and a trend toward a survival advantage for
treatment with FP. This analysis shows that joint considera-
tions of quality of life and survival result in a substantial
increase in QALYs favoring treatment with FP. Based on
these data, the inhaled corticosteroid FP appears cost-
effective for the treatment of COPD. Conﬁrmation or refu-
tation of this result may be achieved once the Towards a
Revolution in COPD Health (TORCH) study reports, a large
randomized controlled trial powered to detect mortality
changes associated with the use of FP alone, or in combina-
tion with salmeterol, which is also collecting resource use
and utility data suitable for estimating cost-effectiveness.
Keywords: chronic obstructive pulmonary disease, cost-
effectiveness, incremental cost-effectiveness ratio, missing
data.
Introduction
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) deﬁnes chronic obstructive pulmo-
nary disease (COPD) as a chronic disease characterized
by nonreversible airﬂow limitation that is usually pro-
gressive and associated with an abnormal inﬂamma-
tory response of the lungs to particles and gases, and
particularly tobacco smoke [1]. The symptoms of
COPD, resulting from airway irritation and altered
lung function, include coughing, sputum production,
breathlessness, wheezing, and chest pain [1]. In addi-
tion to chronic symptoms, subjects with COPD may
also experience episodes of acute exacerbations, com-
monly triggered by respiratory infection [1] that fre-
quently require intense medical follow-up in hospital,
sometimes including respiratory therapy [2]. The
impact of COPD on health-related quality of life is
well-documented; worse health is associated with an
increased likelihood of hospitalization [3], more fre-
quent exacerbations [4], and increased mortality [5]. A
recent study has shown that frequent exacerbations are
associated with a more rapid decline in health status
[6].
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With an approximate global prevalence of 600 mil-
lion and 2.5 million deaths recorded worldwide annu-
ally, COPD was estimated to be the eleventh leading
cause of disability and the ﬁfth leading cause of mor-
tality in 2000 [7]. Because of aging populations, air
pollution [8], and rapid increases in the rate of ciga-
rette smoking in some (mostly developing) countries
[9–13] and among speciﬁc subgroups [14], it is pro-
jected that, by 2020, COPD will become the ﬁfth lead-
ing cause of disability and third leading cause of death
in the world [15].
Available treatments for moderate to severe COPD
mostly comprise single agent or combination bron-
chodilator therapy (i.e., short or long acting β2-
agonists, inhaled anticholinergics and theophyllines),
and oral corticosteroids to manage COPD exacerba-
tions [16,17]. Few long-term studies have investigated
the effect of inhaled corticosteroids on lung function
and exacerbations. The Inhaled Steroids in Obstructive
Lung Disease in Europe (ISOLDE) study was a rand-
omized, placebo-controlled clinical trial comparing
inhaled ﬂuticasone propionate (FP) versus placebo in
751 subjects with moderate to severe COPD [18,19].
The objective was to determine the effect of treatment
on lung function, exacerbations, and health status over
the 3-year follow-up of the trial. The results showed
that, although FP did not reduce the annual rate of
decline in lung function compared with placebo, sig-
niﬁcant beneﬁts were achieved in terms of reduced fre-
quency of exacerbations and a reduction in the decline
of health status [18,19]. Because of their strong asso-
ciation with prolonged hospitalization and death [4],
COPD exacerbations are often interpreted as a perti-
nent health outcome. In that regard, the ISOLDE study
showed that inhaled corticosteroids could potentially
yield important beneﬁts.
Although a main focus of the original clinical trial
was deterioration of health status as measured by the
disease-speciﬁc St George’s Respiratory Questionnaire
(SGRQ) [20], the generic SF-36 health status measure
was also included in ISOLDE [21]. The reduction in
rate of health status deterioration associated with FP
treatment occurred over all domains of the SGRQ and
the Physical Function, Physical Role, Energy/Vitality,
and Mental Health domains of the SF-36 [21]. The
recent publication of an algorithm to translate SF-36
scores into utility scores [22] offers, for the ﬁrst time,
the potential for the improvement in health status
associated with treatment already observed in ISOLDE
to be translated into a gain in quality-adjusted life-
years (QALYs). QALYs explicitly combine length and
quality of life in a single measure and are the preferred
metric in health economic evaluations for bodies such
as the National Institute for Clinical Excellence
(NICE) in the UK [23], because they allow the direct
comparison of treatment cost-effectiveness between
disease areas. The aim of the present study is to assess
the cost-effectiveness of FP for the treatment of COPD,
by performing an economic evaluation of the ISOLDE
trial data, estimating costs and QALYs over the 3-year
follow-up of the trial.
Methods
After the early withdrawal of nine patients before dou-
ble-blind randomization in the ISOLDE trial, 742
patients were available for analysis. The economic
analysis was conducted from a UK public sector
(Health and Personal Social Services) perspective over
the 3 years of the clinical study. When reporting cost-
effectiveness results costs and effects were discounted
at the rate of 3.5% per annum, the rate currently rec-
ommended in the most recent guidance from NICE in
the UK [23].
Calculation of Utility Scores
In the ISOLDE study, the generic SF-36 instrument
was administered at baseline and every 6 months for
the 3 years of follow-up, generating a maximum of
seven possible observations for each patient enrolled in
the trial. Brazier and colleagues have reported work on
deriving a reduced health status index from the SF-36
that they term the SF-6D [24] and more recently, they
have published an algorithm that allows the estimation
of utility scores for all states of the SF-6D index [22].
Following this published algorithm, the SF-36 scores
observed in the trial were converted to utility scores.
QALYs were calculated assuming linear interpolation
between each observed 6-month visit [25] and calcu-
lating the area under the curve to give a QALY score
per patient over the trial period. The mean QALY dif-
ference was adjusted for a slight (nonsigniﬁcant) dif-
ference between the baseline utility scores between the
two arms [26], which has been shown to be important
for the unbiased assessment of mean QALY differences
[27].
Estimation of Costs
In addition to the cost of treatment, six categories of
resource were collected as part of ISOLDE: rescue
medication use, concomitant medication use, visits to
the general practitioner, visits to outpatient clinics, vis-
its to the emergency room, and inpatient hospital
stays. Unit costs for medications were obtained from
the British National Formulary (comparison of the
contemporary  price  of  FP  shows  that  it  remains  at
the same cost as the base year of this study [28]), and
the unit costs of health service contacts from a pub-
lished compendium of unit cost ﬁgures [29]. For the
purposes of this analysis, costs were accrued for the
same 6-month periods relating to the visits at which
health status was measured. Accumulating these costs
over the maximum six periods (3 years) gave the per-
patient total cost for the study. The costing employs a
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base year of 1998 to 1999, corresponding to the year
in which trial ended.
Missing Data Due to Attrition
One important issue observed in the ISOLDE clinical
trial was the high rate of withdrawals over the 3 years
of follow-up. Experiencing COPD-related adverse
events was also stated as one of the main reasons for
dropping out and the overall rate of dropout was
higher in the placebo group at 53% of subjects com-
pared with 43% in the FP group [20]. Consequently, a
large amount of data on periodic costs and utilities had
missing values over the 3 years of the clinical study,
which prevented the total cost and QALY scores being
calculated for these patients. Although the original
clinical study reported 36 deaths during the study
period in the placebo group compared with 32 among
those allocated to FP, these represented only deaths
before dropout from the study. Retrospective exami-
nation of death records revealed that there were in fact
58 deaths among those allocated placebo within the 3-
year period of the study compared with just 45 in the
FP arm of the study. Having adjusted for data known
to be unavailable as a result of death, the rate of miss-
ing data observations was estimated to be 20% for
costs and 34% for SF-36 information at scheduled
visit dates (Table 1).
A preliminary analysis of QALYs and cost, includ-
ing a breakdown of costs by resource use category,
was conducted based only on the complete cases
(complete information was available for the life-year
analysis as described above). This provides a useful
reference point for comparison with the full imputa-
tion analysis described below. When combining com-
plete cases of cost and QALYs (and life-years) to
estimate cost-effectiveness the full set of complete case
information for each component of the calculation
was retained. That is, cost data were not dropped if
the patient did not have a complete utility score and
vice versa. Nevertheless, covariance information for
conﬁdence interval (CI) calculation could only be esti-
mated from patients that had both cost and effect
information available.
Imputation of Missing Information
For cost and utility information that was missing after
dropout from the study, but before death/end of the 3-
year follow-up period, the values of the missing obser-
vations were imputed. Following Oostenbrink and
colleagues [30], an imputation approach based on
propensity scoring was employed with baseline varia-
bles including age, smoking status, sex, pulmonary
function (forced expiratory volume in 1 s), body mass
index categories, and disease-speciﬁc SGRQ score,
entered into a logistic regression to predict the chance
of a missing value. In addition, one-period-lagged val-
ues of the relevant cost or utility score were included as
explanatory variables. To avoid missing lagged values,
the imputation equations were ﬁtted sequentially and
imputed lagged values were used where appropriate.
The predicted probability from this regression is the
propensity score and on the basis of this predicted
probability, the available data were arranged into
quintiles. Where cost data or a utility score were miss-
ing, a replacement value was selected at random from
the available data points within the same quintile. By
choosing a value at random within the same quintile
the principle of multiple imputation could be
employed [31]. Multiple imputation procedures are
considered more valid than single imputation methods
because instead of ﬁlling in a single value and treating
it as known, as would be the case if a single value
based on the closest propensity match was used, in
each imputation uncertainty in the imputation process
is taken into account such that the imputed data points
represent a random sample of the missing values [32].
Although the standard approach is to use a small
number of imputed data sets in a multiple imputation
process, the recent International Society for Pharmaco-
economics and Outcomes Research Task Force on
cost-effectiveness analysis alongside clinical trials sug-
gested that both statistical and imputation uncertainty
could be combined by bootstrapping the whole impu-
tation/estimation process [33]. Therefore, the existing
data set was ﬁrst bootstrapped including the missing
data and then the imputation process was employed
to ﬁll in the missing values. The whole bootstrap/
Table 1 Missing data observations and implications for complete cases
Quality of life utility Total costs
Placebo
(n = 370)
FP
(n = 372)
Placebo
(n = 370)
FP 
(n = 372)
Maximum number of observations 2220 2232 2220 2232
Total observations* 2077 2129 2077 2129
Of which complete 1279 1459 1616 1749
% observations missing 38 31 22 19
Total cases complete 121 154 242 269
% cases missing 67 59 35 28
*Total observations are less than maximum number of observations because of deaths within the study period and do not include the baseline assessment of utility.
FP, ﬂuticasone propionate.
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imputation procedure was then repeated 1000 times
to generate an overall estimate of uncertainty that
includes uncertainty in the imputation process.
In a more qualitative sensitivity analysis of the
imputation procedure, a best and worst case analysis
was also performed. For the best case, imputed values
for the costs and utilities in the FP group were based
on the mean cost and utility in the ﬁrst period for all
completers, and for the placebo group the mean cost
and utility in the last available period for subjects that
eventually dropped out, when costs were generally
higher and utilities lower. For the worst case scenario,
we applied the reverse logic by imputing values for FP
that were based on mean cost and utility for the last
period before subjects dropping out and for the pla-
cebo group we used the mean costs and utility in the
ﬁrst period for all completers. This alternative impu-
tation approach allowed the importance of the chosen
imputation method to be assessed and in particular
allows the assessment of the sensitivity of the results to
the possibly nonignorable nature of the missing data.
Economic Analysis
The three outcomes estimated for the economic anal-
ysis were cumulative costs, life expectancy, and qual-
ity-adjusted life expectancy over 3 years. To determine
cost-effectiveness, we calculated the incremental cost-
effectiveness ratio (ICER) as the ratio of the difference
in costs between FP and placebo to the difference in
effects. Lower values of the ratio suggest that the ben-
eﬁts of treatment come at lower cost and therefore
indicate better value for money. Both the nonparamet-
ric bootstrap and Fieller’s theorem [34,35] were
employed to generate CIs for cost-effectiveness esti-
mates based on complete data, whereas just the non-
parametric bootstrap was used to represent the
combination of statistical/imputation uncertainty
where multiple imputation was employed. Uncertainty
surrounding the ICER was also presented on the cost-
effectiveness plane [36,37].
Results
The mortality curves for FP and placebo are presented
in Figure 1. The difference in survival was estimated to
be 23 days or 0.06 life-years over the study period,
although this difference did not reach statistical signif-
icance at conventional levels (P = 0.11). No imputa-
tion was necessary for mortality because the data were
complete. The extent of missing information relating
to cost and utility is summarized in Table 1 and shows
that approximately 20% of the observations relating
to cost and 34% of the observations relating to utility
were missing. Furthermore, data were more likely to
be missing from the placebo than the treatment group.
These missing observations have a more profound
effect on complete cases with just 69% of patients hav-
ing a complete set of cost data and only 37% of
patients having complete information on utilities. The
breakdown of costs into treatment costs, other medi-
cation use, primary care contacts and secondary care
visits is shown in Figure 2 by treatment allocation.
This shows clearly that the additional costs of FP are
only partially offset by a (nonsigniﬁcant) reduction in
hospitalization costs with no apparent effect on other
categories of cost.
A complete case analysis based only on those
patients that had full and complete data for the 3-year
follow-up of the study is reported in Table 2, with all
CIs based on the nonparametric bootstrap; parametric
intervals based on Fieller’s method produced very sim-
ilar outcomes. These results show that FP is associated
with a signiﬁcantly increased cost, but also a beneﬁt in
terms of QALYs gained (bordering on statistical sig-
niﬁcance) over the 3-year study period. These results
are presented on the cost-effectiveness plane in terms
of both life-years and QALYs gained in Figure 3,
where the close correspondence between the bootstrap
and the assumption of multivariate normality of the
joint density of costs and effects is apparent. Despite
these  promising  results  there  are  two  concerns  with
the complete case analysis presented in Table 2 and
Figure 3. First, the reduced sample size as a basis for
this analysis is wasteful of information, because of
excluding patients with some information, but who are
missing at least one data point, with consequent loss of
power. Second, the results may be biased if the data are
not missing completely at random.
The imputation results for the propensity scoring
method are reported in Table 3 and Figure 4 where CIs
are now calculated nonparametrically and include
both sampling and imputation uncertainty by nesting
the imputation within the bootstrap. The incremental
Figure 1 Failure curves for time to death in the placebo and ﬂuticasone
propionate (FP) arms. Separation shown is nonsigniﬁcant (P = 0.11).
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costs of FP versus placebo was estimated to be £1021
(95% CI £619–1338) with an additional effect of 0.11
QALYs (0.04–0.20). The discounted cost-effectiveness
for the within-trial period was estimated to be £17,700
per life-year gained (£6900 to ∞) and £9500 per QALY
gained (£4300–26,500). The results of the sensitivity
analysis for the best case scenario resulted in an ICER
point estimate of £5200 whereas the worst case sce-
nario yielded an ICER of £13,200.
The conﬁdence ellipses of Figure 2 (Fieller’s method
assumptions) based on complete case analysis are over-
laid in Figure 4 and show how the imputation
approach changes the location of the joint distribution
slightly, but that the main effect is to reduce the vari-
ance of the estimates, particularly for QALYs gained
where missing data observations were greatest.
Discussion
In this study, we have estimated the cost-effectiveness
of FP versus placebo using data from the previously
published ISOLDE study. It is only after the publica-
Figure 2 Costs split by treatment group for
placebo and control arms (based on complete
cases). Treatment, costs of study medication;
Other meds, all other medications costs; Hosp,
costs of inpatient and emergency department
visits; OP/GP, costs of visits to outpatient
departments or primary care physicians. P-
values shown are for standard t-tests for differ-
ence between treatment groups for each
category.
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Table 2 Cost effectiveness analysis based only on complete cases
N Placebo (95% CI) N FP (95% CI) Difference (95% CI)
Life-years 370 2.75 (2.68–2.80) 372 2.81 (2.76–2.86) 0.06 (−0.01–0.14)
QALYs 121 1.74 (1.62–1.84) 154 1.88 (1.79–1.97) 0.12* (−0.00–0.25)
Cost 242 £1341 (£1110–1600) 269 £2494 (£2274–2715) £1,153 (£820–£1472)
Cost per life-year (£)
Undiscounted 18,400 (7500–∞)
Discounted 20,000 (8100–∞)
Cost per QALY (£)
Undiscounted 9,500 (4300–∞)
Discounted 9,600 (4400–∞)
*After controlling for baseline utility.
CI, conﬁdence interval; FP, ﬂuticasone propionate; QALY, quality-adjusted life-year.
Table 3 Cost-effectiveness analysis based on full imputation
N Placebo (95% CI) N FP (95% CI) Difference (95% CI)
Life-years 370 2.74 (2.68–2.80) 372 2.81 (2.76–2.85) 0.06 (−0.01–0.14)
QALYs 370 1.74 (1.67–1.80) 372 1.86 (1.82–1.93) 0.11* (0.04–0.20)
Cost 370 £1509 (£1286–£1879) 372 £2530 (£2341–£2774) £1,021 (£619–£1338)
Cost per life-year (£)
Undiscounted £16,300 (£6400–∞)
Discounted £17,700 (£6900–∞)
Cost per QALY (£)
Undiscounted £9,600 (£4200–£26,500)
Discounted £9,500 (£4300–£26,500)
*After controlling for baseline utility.
CI, conﬁdence interval; FP, ﬂuticasone propionate; QALY, quality-adjusted life-year.
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Figure 3 Complete case cost-effectiveness on the cost-effectiveness plane: left panel shows cost per life-year; right panel shows cost per quality-adjusted
life-year (QALY). Bars show 95% conﬁdence intervals for incremental cost and effect crossing at the point estimates; joint distribution of incremental cost
and effect is shown using 5%, 50%, and 95% conﬁdence ellipses.
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tion of an algorithm for converting data on the SF-36
instrument to utility scores suitable for calculating
QALYs that it has been possible to directly estimate
cost-utility results from ISOLDE. ISOLDE was not
designed to have sufﬁcient power to detect differences
between groups for mortality, but nevertheless showed
a trend toward reduced mortality. The results of the
analysis reported here show that combining that trend
with the signiﬁcant improvement previously reported
in health status resulted in a highly signiﬁcant QALY
gain. Nevertheless, given the retrospective nature of
the analysis and the fact that the study was not pow-
ered for mortality differences, these results should be
considered as hypothesis generating.
The high rate of withdrawal in the clinical study
required the use of imputation techniques to handle
missing data. Of particular concern was that there was
a strong indication that the attrition was related to
adverse outcomes with those experiencing COPD-
related adverse events representing the majority of
patients  dropping  out  of  the  study.  This  means  that
the  underlying  pattern  of  missingness  was  certainly
not completely at random and may be informative.
Informative missingness is problematic in that any use
of statistical techniques based on observed data are
potentially misleading, and modeling unobserved data
requires assumptions that are difﬁcult to verify. Our
solution was to use propensity scoring as the base case
analysis, because this at least imputes from the group
of patients that had a similar propensity to have miss-
ing values and might therefore account for some of the
informative nature of those missing values. In addi-
tion, a more qualitative analysis of replacing missing
values examined “best case” and “worst case” scenar-
ios, from the perspective of the intervention under
study, and revealed that even if missing values were
deliberately stacked against the intervention, the esti-
mate of cost-effectiveness was still within acceptable
limits. That the estimated cost-effectiveness was insen-
sitive to the choice of imputation method used (even
under extreme assumptions) suggests that the level of
missingness in ISOLDE does not invalidate the results.
The comparison between the complete case analysis
and the imputation analysis raises a number of inter-
esting issues. It is quite clear that the main impact of
using the imputed data has been to reduce the vari-
ance—this is due to the fact that many more data
points are now being used in the analysis with conse-
quent increase in precision of estimation. The effect on
the point estimates is less remarkable. There was a
slight reduction in both the point estimate of the cost
difference and the incremental QALY gain following
imputation, which had little impact on the estimated
cost-effectiveness ratio. Under an assumption that
missing values are nonignorable and quality of life out-
comes are worse for those dropping out, it would be
reasonable to expect that the QALY gain would
increase following imputation (due to the lower attri-
tion rate in the FP arm), but this was not the direction
of the effect that was observed, although given the
overall uncertainty we are reluctant to read too much
into this. Nevertheless, the propensity scoring
approach is only really valid for MAR patterns of
missingness. Although a number of authors have sug-
gested methods for handling missingness that would
attempt to impute observations based on the assump-
tion that missing values are nonignorable [38], formal
testing of those assumptions is difﬁcult in a statistical
sense. Although potentially open to criticism, the
MAR assumption in this case is most likely to bias
against the true cost-effectiveness of FP, because any
assumption of poorer outcomes among missing obser-
vations would accentuate the difference between the
arms because of the differential dropout.
The original costing of ISOLDE was undertaken
using a cost base year corresponding to the year that
the trial closed. Although this may seem to be out of
date for a current analysis, we have not attempted to
update the costing for two main reasons. First, for
some resource use categories (such as concomitant
medications) the individual resource use quantities are
not available, and so any updating of costs could only
be achieved through the use of a health service inﬂa-
tion index. Second, the price of FP has not changed
since the trial was undertaken. Therefore, the analysis
presented here is conservative, because the cost of FP is
effectively the current price, and any cost-savings from
the reduction in other health service resource use asso-
ciated with treatment are currently valued using 1998/
99 unit costs.
The results of this study suggest that inhaled FP is
associated with increased quality-adjusted survival
when compared with placebo. This adds support to
the need to account for the quality-of-life considera-
tions when evaluating treatments for COPD. These
beneﬁts came at relatively small overall incremental
costs resulting in a favorable cost-effectiveness ratio
for FP compared with placebo. For example, although
NICE have strenuously denied the existence of a single
cost-per-QALY threshold, they have indicated that
they would be unlikely to reject a treatment in the
range from £5000 to £15,000 per QALY purely on
cost-effectiveness grounds [39]. The effect of inhaled
corticosteroids alone or in combination with a long
acting beta-agonist on survival is currently being inves-
tigated in TORCH (TOwards a Revolution in COPD
Health), a large randomized controlled trial involving
more than 6000 patients comparing the effects of FP
alone, or in combination with salmeterol, with placebo
[40]. This study should provide further evidence on the
effectiveness and cost-effectiveness of inhaled corticos-
teroids alone and in combination and could provide
the deﬁnitive analysis to conﬁrm or refute the ISOLDE
results presented here.
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